

September 14, 2020



Monopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020

WILMETTE, Ill., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced that Chandler D. Robinson, MD, Chief Executive Officer, will present a corporate update at the H.C. Wainwright 22nd Annual Global Investment Conference, Healthcare & Biotech Track. The conference will be held virtually.

Presentation Details:

Date: Wednesday, September 16, 2020

Time: 1:30 PM EDT

Location: Virtual

<https://hcwevents.com/>

For more information, please contact investor relations at kimtsu@monopartx.com.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive[®] for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19. For more information, visit: www.monopartx.com.

About H.C. Wainwright 22nd Annual Global Investment Conference

The H.C. Wainwright 22nd Annual Global Investment Conference featuring a Healthcare & Biotech track, will be a virtual event which includes keynote speakers, presenting companies, investor one-on-one meetings, networking opportunities and an evening of virtual entertainment. The event will occur from September 14-16, 2020. For more information on the event, visit <https://hcwevents.com/>.

Source: Monopar Therapeutics Inc.